Otonomy Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 10, 2015 16:21 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
October 07, 2015 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
October 05, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Label Expansion Indication
March 26, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Submits New Drug Application to the FDA for AuriPro(TM)
February 26, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...